A PYMNTS Company

US: Hospira gets antitrust claims tossed

By  |  January 7, 2020

Pfizer unit Hospira dodged antitrust claims in Manhattan federal court over its alleged scheme to monopolize a group of generic drugs it had promised to sell exclusively to Apotex.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The lawsuit accuses Hospira of breaching a supply agreement between Apotex and Orchid Chemicals Pharmaceuticals after agreeing to be bound by the contract when it acquired the rights to five drugs from Orchid. The case was filed in the US District Court for the Southern District of New York, originally without any antitrust claims.

    Full Content:

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.